Physician profile
Jon P Durrani
NPI 1932495157
$381,583.17
in general payments reported to CMS, 2019-2025
63 companies · $104K in 2025
The $104K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,542 · 2020: $2,098 · 2021: $11K · 2022: $55K · 2023: $87K · 2024: $115K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $215K · Consulting Fee: $49K · Travel and Lodging: $31K · Food and Beverage: $12K · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214,533.16 |
| Consulting Fee | $48,717.00 |
| Travel and Lodging | $30,856.58 |
| Food and Beverage | $12,221.38 |
| Education | $317.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $123,464.72 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Alexion Pharmaceuticals, INC. | $114,903.16 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $85,388.73 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $28,259.61 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Janssen Biotech, INC. | $11,733.37 | 2025 | |
| Amgen INC. | $2,744.20 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $2,738.66 | 2019-2025 | Xywav |
| Allergan, INC. | $1,263.48 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $1,098.44 | 2019-2021 | |
| Biogen, INC. | $872.25 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $865.31 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $861.34 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $685.98 | 2020-2025 | |
| Lilly USA, LLC | $586.55 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $478.46 | 2021-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Durrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.